Allogeneic Anti-CD19 CAR-NK Cells QN-019a

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR-NK cells QN-019a recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.

**Synonyms:** - Allogeneic CD19-targeting CAR-NK Cells QN-019a - QN 019a - QN-019a - QN019a